Risk Management

New and Revised Resources

August 6, 2020

We are pleased to provide some new and revised resources; please use the links to access them.

Ophthalmic anesthesia claims

OMIC policyholder Dr. Michael Morley, anesthesiologist Dr. Karin Nanji, and OMIC Patient Safety Manager Anne Menke analyzed 10 years of ophthalmic anesthesia claims. “Ocular Anesthesia-Related Closed Claims from Ophthalmic Mutual Insurance Company 2008-2018” is available in the July 2020 issue of Ophthalmology.

https://www.aaojournal.org/article/S0161-6420(19)32371-1/fulltext

New: DURYSTA recommendations and consent

The FDA approved the DURYSTA implant in June 2020 for the treatment of open-angle glaucoma. OMIC prepared risk management recommendations to address the risk of endothelial cell loss and a sample consent form to help educate patients about the risks and benefits.

DURYSTA recommendations/consent form

Revised: recommendations and consent forms for intravitreal triamcinolone acetonide

Ophthalmologists regularly administer this medication. We have updated our recommendations and prepared consent forms for Kenalog and Triesence.

• Intravitreal injection of Kenalog or Triesence
• Kenalog consent form
• Triesence consent form

Call the OMIC Hotline for confidential advice on any risk management issue. We’re here to help!
Phone: 800.562.6642 (Press 4)
Email:  riskmanagement@omic.com